Scarica l'app Stockscreener
54.99
2.59%
1.39
Grail Inc Borsa (GRAL) Ultime notizie
Is GRAIL (GRAL) Turning Superpower Partnership Into a Scalable Edge in Preventative Oncology? - simplywall.st
Price-Driven Insight from (GRAL) for Rule-Based Strategy - news.stocktradersdaily.com
GRAL SEC FilingsGrail Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRAIL (GRAL) Price Target Decreased by 10.52% to 85.07 - MSN
GRAL Investors Invited to Join Fraud Investigation - National Today
Here’s what analysts are saying about Grail Inc. (GRAL) - MSN
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
GRAL Technical Analysis & Stock Price Forecast - Intellectia AI
Grail (GRAL) rated buy by Guggenheim on Galleri potential - MSN
GRAIL, Inc. (GRAL) stock price, news, quote and history - Yahoo Finance Singapore
GRAIL, Inc. (GRAL) interactive stock chart - Yahoo Finance Singapore
GRAIL, Inc. (GRAL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Superpower partners with GRAIL to offer multi-cancer blood test By Investing.com - Investing.com Australia
Grail partnering with Superpower to offer Galleri cancer early detection test - MSN
Superpower Announces Strategic Partnership With GRAIL For Multi-Cancer Early Detection Test - tradingview.com
Superpower partners with GRAIL to offer multi-cancer blood test - Investing.com
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection - PR Newswire
Why Grail’s Stock Is Surging Again Today - TipRanks
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - PR Newswire
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
Adobe Illustrator just got the holy grail of illustration tools - Fast Company
Grail (GRAL) Rated Buy by Guggenheim on Galleri Potential - Insider Monkey
GRAIL (GRAL): Guggenheim Lowers Price Target to $75, Maintains B - GuruFocus
UBS (AMUB) offers 15.30% autocallable notes linked to GRAIL (GRAL) - Stock Titan
GRAIL, Inc. Opens with 5.11% Gain, Outperforming S&P 500's 1.01% Rise - Markets Mojo
GRAIL, Inc. Stock Hits Day Low of $47.55 Amid Price Pressure - Markets Mojo
Guggenheim Cuts GRAIL Price Target to $75 - National Today
GRAIL (NASDAQ:GRAL) Given New $75.00 Price Target at Guggenheim - MarketBeat
Grail price target lowered to $75 from $130 at Guggenheim - TipRanks
JPMorgan Chase Boosts Stake in Cancer Screening Firm GRAIL - National Today
JPMorgan Chase & Co. Raises Stake in GRAIL, Inc. $GRAL - marketbeat.com
GRAIL (NASDAQ:GRAL) Stock Price Down 7.5%Time to Sell? - marketbeat.com
Why GRAIL Inc Shares Keep Sliding This Week - TipRanks
Vanguard disaggregates holdings; GRAIL now shows 0% ownership (GRAL) - stocktitan.net
Here's Why Grail Stock Soared Higher This Week - Yahoo Finance
Here's Why Grail Stock Soared Higher This Week - The Motley Fool
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went ... - caledonianrecord.com
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - chartmill.com
Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures - AD HOC NEWS
Why Grail Stock Is Surging Back With Force - TipRanks
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures - AD HOC NEWS
Illumina Inc. stock faces ongoing challenges from Grail divestiture and genomics market pressures - AD HOC NEWS
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWS
(GRAL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path - Investing.com Canada
One Fin Capital Exits GRAIL Position, Sells 380,000 SharesNews and Statistics - IndexBox
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path By Investing.com - Investing.com South Africa
Hims latest offering, Grail's Galleri cancer test, fails U.K. study - MSN
Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind - AD HOC NEWS
This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month - The Motley Fool
0.17%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):